Treatment Information

Back

Prostate Cancer treatment details. Hormone.

Indiana University, Indianapolis, IN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Indianapolis, IN
Treatments:HormoneHospital:Indiana University
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase II study involved 33 patients with hormone-refractory prostate cancer. The median age was 74 years. All but one patient had bone metastases.

Treatment: The treatment consisted of an estrogen derivative: 2-Methoxyestradiol. The patients were separated into two groups and given a low or high dose of 2-methoxyestradiol.

Toxicity: There were no grade-4 toxicities. Grade 3 toxicities include elevated liver enzymes.

Results: The median overall survival was not reported, but the higher-dose group was associated with a longer time on therapy. The authors concluded, "2-methoxyestradiol is well tolerated with evidence of anticancer activity at the 1,200 mg/d dose."

Support: EntreMed provided financial support for this study, and several of the authors are employees of EntreMed. EntreMed manufactures and markets 2-methoxyestradiol.

Correspondence: Christopher Sweeney, MD



Back